Trading Sections
Climb Bio: How a modified antibody could change the market for kidney diseases
Climb Bio (CLYM) focuses on its lead product CLYM116 aimed at the addressable market for IgA Nephropathy...
Alibaba: Specific Payback Cycles and a $175 Price Target Bring AI Cloud into Focus
Alibaba (BABA) is increasingly focusing on the expansion of AI infrastructure and cloud services, funded...
Ionis Pharmaceuticals: A Rare Milestone and the Strategic Shift in Neurology - Experts See 98% Share Price Potential!
The FDA approval for Zanvastro, 19 days before the PDUFA date, opens the door to an untapped market for...
Fuelcell Energy: Price Target of 30 USD Meets Billion-Dollar Order Backlog
The strategic focus on data centers drives the order backlog of Fuelcell Energy (FCEL) to over 3.6 billion...
Fervo Energy Company: 400 MW Contract with Google and Over 150% Upside Potential!
Fervo Energy (FRVO) employs modified drilling techniques for weather-independent, emissions-free geothermal...
Latigo Biotherapeutics: Guggenheim's buy recommendation with over 100% upside potential draws attention to NaV1.8 inhibitors
Latigo Biotherapeutics (LTGO) focuses on non-opioid analgesics for acute and chronic pain. On September...
Attovia Therapeutics Inc.: Leerink Initiates Coverage on Stock After Successful IPO with Price Target of $52!
Attovia Therapeutics (ATTO) develops complex biologics for immune-mediated diseases using its proprietary...
Iren Ltd.: From Post-Earnings Sell-Off to $90 Target - H.C. Wainwright Sees a Buying Opportunity
Iren Ltd. (IREN) is undergoing a strategic shift from Bitcoin mining to AI cloud infrastructure. The...
Zymeworks Inc.: FDA approval for Ziihera triggers target price increase to 55 USD and milestone payment
The business model of Zymeworks Inc. (ZYME) combines internal research with strategic partners, relieving...
Methode Electronics: Data Center Expansion and E-Mobility as Revenue Drivers - Craig-Hallum Sets Target Price of $30
Craig -Hallum rates Methode Electronics (MEI) on August 25 with a buy recommendation and a target price...
Shattuck Labs: Raymond James sees the DR3 antibody as a growth driver - Expert sees 130% price potential
Raymond James has assigned a "Strong Buy" rating to the stock of Shattuck Labs (STTK) and has set an...
Ultragenyx: The first FDA approval in the gene therapy segment - Experts raise the price target to $103!
The US health authority FDA has granted accelerated approval for the gene therapy Genglycos by Ultragenyx...
Nuvation Bio: Hidden Valuation Reserves in the Precision Oncology Sector?
Nuvation Bio (NUVB) looks at a strong Q2 and liquidity of $661 million. JPMorgan initiated coverage on...
adesso SE: AI contracts worth €73 million bring industry discount into focus - Berenberg sees 121% price potential
Analysts at the private bank Berenberg see a price target of €128 for adesso SE (i.) and point to the...
Eton Pharmaceuticals: 99% Revenue Jump from Rare Diseases and the Path to a 35% Margin
The focus of Eton Pharmaceuticals (ETON) on therapeutics for rare diseases led to a revenue growth of...
AbSci: AI-Based Antibody Development Meets Billion-Dollar Hair Loss Market - H.C. Wainwright Sees 74% Upside Potential
Looking at the top price targets set by analysts, on August 12, AbSci Corp. (ABSI) stands out positively...
Olema Pharmaceuticals: Financial Headwinds Meet Billion-Dollar Market Potential - Experts See Up to 400% Price Potential!
Olema Pharmaceuticals (OLMA) ended the second quarter with cash equivalents amounting to $461.1 million...
Deep Fission: The Challenging Path from 31 Million USD Quarterly Loss to Commercial Scaling - Seaport Sees 178% Price Potential
The business model of Deep Fission (FISN) is based on placing modular pressurized water reactors at...
CoreWeave: Between Margin Pressure and Profit Potential in AI Infrastructure - Deutsche Bank Research Sees 72% Upside Potential
Deutsche Bank has reiterated its rating for CoreWeave (CRWV) on August 7, maintaining a "Buy" recommendation...
Amplitude Inc.: AI Integration as a Catalyst for Double-Digit Growth? - Needham Sees 70% Price Potential!
Amplitude Inc. (AMPL) was able to break out yesterday in response to strong fundamentals and an upward...
Arvinas: FDA approval for VEPPANU serves as revenue and earnings driver - Two analyst firms see 122% price potential each!
Arvinas (ARVN) is currently in the spotlight for investors and analysts. The business model is based...
Snap: 19% Revenue Increase and Rising Advertising Revenue as Indicators of Operational Turnaround - Barclays Raises Target to $16!
Fundamentals of the Business Model Snap Inc. (SNAP) operates as a technology and social media company....
D-Wave Quantum: Partnership with Nasdaq Verafin - Wedbush Sees 100% Upside Potential for the Stock!
D-Wave Quantum (QBTS) follows a dual-platform approach in quantum computing. A new partnership with...